Loading
PDBj
メニューPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

5EX3

Crystal structure of human SMYD3 in complex with a VEGFR1 peptide

5EX3 の概要
エントリーDOI10.2210/pdb5ex3/pdb
関連するPDBエントリー5EX0
分子名称Histone-lysine N-methyltransferase SMYD3, VEGFR1 peptide, ZINC ION, ... (6 entities in total)
機能のキーワードset domain, methylation, chromatin, cancer, transferase
由来する生物種Homo sapiens (Human)
詳細
細胞内の位置Cytoplasm : Q9H7B4
タンパク質・核酸の鎖数2
化学式量合計51785.10
構造登録者
Qiao, Q.,Fu, W.,Liu, N.,Wang, M.,Min, J.,Zhu, B.,Xu, R.M.,Yang, N. (登録日: 2015-11-23, 公開日: 2016-03-09, 最終更新日: 2017-10-18)
主引用文献Fu, W.,Liu, N.,Qiao, Q.,Wang, M.,Min, J.,Zhu, B.,Xu, R.M.,Yang, N.
Structural Basis for Substrate Preference of SMYD3, a SET Domain-containing Protein Lysine Methyltransferase
J.Biol.Chem., 291:9173-9180, 2016
Cited by
PubMed Abstract: SMYD3 is a SET domain-containing N-lysine methyltransferase associated with multiple cancers. Its reported substrates include histones (H3K4 and H4K5), vascular endothelial growth factor receptor 1 (VEGFR1 Lys(831)) and MAP3 kinase kinase (MAP3K2 Lys(260)). To reveal the structural basis for substrate preference and the catalytic mechanism of SMYD3, we have solved its co-crystal structures with VEGFR1 and MAP3K2 peptides. Our structural and biochemical analyses show that MAP3K2 serves as a robust substrate of SMYD3 because of the presence of a phenylalanine residue at the -2 position. A shallow hydrophobic pocket on SMYD3 accommodates the binding of the phenylalanine and promotes efficient catalytic activities of SMYD3. By contrast, SMYD3 displayed a weak activity toward a VEGFR1 peptide, and the location of the acceptor lysine in the folded kinase domain of VEGFR1 requires drastic conformational rearrangements for juxtaposition of the acceptor lysine with the enzymatic active site. Our results clearly revealed structural determinants for the substrate preference of SMYD3 and provided mechanistic insights into lysine methylation of MAP3K2. The knowledge should be useful for the development of SMYD3 inhibitors in the fight against MAP3K2 and Ras-driven cancer.
PubMed: 26929412
DOI: 10.1074/jbc.M115.709832
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.408 Å)
構造検証レポート
Validation report summary of 5ex3
検証レポート(詳細版)ダウンロードをダウンロード

226707

件を2024-10-30に公開中

PDB statisticsPDBj update infoContact PDBjnumon